Company News: Bristol-Myers Squibb, Pfizer, Xanodyne Pharmaceuticals and Human Genome Sciences

Share this article:
Bristol Myers-Squibb and Pfizer ended a phase III clinical trial of anticoagulant apixaban in patients with acute coronary syndrome. In an announcement, BMS said it remains committed to developing apixaban in other populations and hinted that a rolling NDA for approval of apixiban for stroke in atrial fibrillation is under way. Apixaban is also in phase III trials for VTE prevention.

FDA's Oncologic Drugs Advisory Committee postponed a Dec. 2 meeting to review BMS cancer drug ipilimumab, trade name Yervoy. According to a source at FDA, a new ad-com date has not been set. BMS submitted a BLA for the treatment of adults with advanced melanoma to the FDA in August, and the original PDUFA date was set for December 25, 2010.

Xanodyne Pharmaceuticals said it is voluntarily pulling its Darvon, Darvon-N and Darvocet-N painkillers from the US market as part of a market-wide withdrawal of all propoxyphene-containing products. FDA determined that the benefits of these products no longer outweigh potential risks, noted Xanodyne in a statement which specifically mentioned propoxyphene's effects on cardiac conduction. A number of other branded and generic versions of the 50-year-old drug are affected, it said.

An FDA advisory panel voted 13-2 to recommend approval of lupus drug Benlysta, which is being developed by Human Genome Sciences and GlaxoSmithKline. The FDA is set to make a final decision on the drug Dec. 9. The agency doesn't have to follow the advice of its advisory panels but generally does.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.